SCHEMBL4499403

SCHEMBL4499403

c1ccc2c(c1)cn1c3ccccc3cnc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.38
GPR3 P46089 1/20 0.38
PTGER4 P35408 2/20 0.35
ALDH1A1 P00352 4/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 1/20 0.33
IDO1 P14902 1/20 0.33
RECQL P46063 1/20 0.33
CYP11B2 P19099 1/20 0.32
ADORA3 P0DMS8 1/20 0.32
LMNA P02545 3/20 0.32
TP53 P04637 2/20 0.32
NFKB1 P19838 1/20 0.32
NFKB2 Q00653 1/20 0.32
RELA Q04206 1/20 0.32
ADORA2A P29274 1/20 0.31
GLA P06280 1/20 0.31
GAA P10253 1/20 0.31
HPGD P15428 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4498650 0.79 KDM4E (0.44) KDM4EGPR3ALDH1A1NPC1CYP11B2
SCHEMBL4501312 0.69 MAPK8 (0.35) KDM4EALDH1A1RAB9ALMNAADORA2A
SCHEMBL4494026 0.69 KDM4E (0.47) KDM4EGPR3ALDH1A1SMN1; SMN2NPC1
SCHEMBL4486727 0.68 ALDH1A1 (0.40) KDM4EGPR3ALDH1A1HPGDL3MBTL1
SCHEMBL2683475 0.68 KDM4E (0.45) KDM4EGPR3ALDH1A1SMN1; SMN2NPC1
SCHEMBL16552325 0.66 PDE2A (0.38) KDM4EALDH1A1NPC1RAB9AADORA3
SCHEMBL1368540 0.66 PARP1 (0.41) KDM4EALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL12145153 0.66 MAPT (0.43) KDM4EALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL15603262 0.66 PARP1 (0.41) KDM4EALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL29881244 0.65 NPSR1 (0.47) KDM4EALDH1A1NPC1RAB9AADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4305098-A1 USE OF AT LEAST ONE SULFUR-CONTAINING AMINO ACID FOR STABILIZING RECYCLED THERMOPLASTICS, STABILIZED RECYCLED THERMOPLASTIC, STABILIZER COMPOSITION, MASTERBATCH, AND MOLDING COMPOUND OR MOLDED PART Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2024-01-17 EP claimed
CN-122029144-A Apparatus and condensation method 三菱化学英国有限公司 2026-05-12 CN disclosed
US-20240043745-A1 USE OF EUGENOL DERIVATIVES AS STABILIZERS, ORGANIC MATERIAL AND EUGENOL DERIVATIVES Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2024-02-08 US disclosed
EP-4305098-A1 USE OF AT LEAST ONE SULFUR-CONTAINING AMINO ACID FOR STABILIZING RECYCLED THERMOPLASTICS, STABILIZED RECYCLED THERMOPLASTIC, STABILIZER COMPOSITION, MASTERBATCH, AND MOLDING COMPOUND OR MOLDED PART Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2024-01-17 EP disclosed
EP-4237484-A1 USE OF EUGENOL DERIVATIVES AS STABILIZERS, ORGANIC MATERIAL AND EUGENOL DERIVATIVES Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2023-09-06 EP disclosed
EP-4127045-A1 USE OF HYDROXYCINNAMIC ACID SALTS FOR STABILISING ORGANIC MATERIALS, STABILISED ORGANIC MATERIAL, METHOD FOR STABILISING ORGANIC MATERIALS, SPECIFIC STABILISERS AND STABILISER COMPOSITIONS Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2023-02-08 EP disclosed
EP-2828353-B1 ISOINDOLO[2,1-A]QUINAZOLINE DERIVATIVES FOR STABILIZATION OF ORGANIC MATERIALS BASF SE (DE) 2016-05-18 EP disclosed
US-9321902-B2 Isoindolo[2, 1-A]quinazoline derivatives for stabilization of organic materials BASF SE (DE) 2016-04-26 US disclosed
US-9321902-B2 Isoindolo[2, 1-A]quinazoline derivatives for stabilization of organic materials BASF SE (DE) 2016-04-26 US disclosed
US-20150087755-A1 ISOINDOLO[2, 1-A]QUINAZOLINE DERIVATIVES FOR STABILIZATION OF ORGANIC MATERIALS BASF SE (DE) 2015-03-26 US disclosed
US-20040053826-A1 Uses of polypeptides TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-03-18 US disclosed
US-20030207863-A1 Preventives and remedies for central nervous system diseases TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-11-06 US disclosed
EP-1331010-A1 PREVENTIVES AND REMEDIES FOR CENTRAL NERVOUS SYSTEM DISEASES Takeda Chemical Industries, Ltd. (JP) 2003-07-30 EP disclosed
EP-1310490-A1 GPR14 ANTAGONIST Takeda Chemical Industries, Ltd. (JP) 2003-05-14 EP disclosed
EP-1308513-A1 USE OF POLYPEPTIDE Takeda Chemical Industries, Ltd. (JP) 2003-05-07 EP disclosed
US-6534496-B1 Prophylactic and/or therapeutic drug for obesity and obesity associated diseasestor diabetes with a reduced risk for central side effects and high universality in usage. Another object of the a lipolytic agent, or a prophylactic and/or TAKEDA CHEMICAL INDUSTRIES, INC. (JP) 2003-03-18 US disclosed
US-20020177593-A1 Agents and crystals for improving excretory potency of urinary bladder TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2002-11-28 US disclosed
EP-1118322-A1 DRUGS FOR IMPROVING VESICAL EXCRETORY STRENGTH Takeda Chemical Industries, Ltd. (JP) 2001-07-25 EP disclosed
US-5620973-A CHOLINESTERASE INHIBITOR; ALZHEIMER*S DISEASE TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1997-04-15 US disclosed
EP-0655451-A1 Tetracyclic condensed heterocyclic compounds for the treatment of senile dementia TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1995-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150087755-A1 ISOINDOLO[2, 1-A]QUINAZOLINE DERIVATIVES FOR STABILIZATION OF ORGANIC MATERIALS SQLE, MYC, CYP4Z1 KDM4E 4802/4885GPR3 1136/4885PTGER4 1385/4885
US-20020177593-A1 Agents and crystals for improving excretory potency of urinary bladder ACHE, BPHL, BCHE KDM4E 306/4885GPR3 1696/4885PTGER4 2690/4885
US-20040053826-A1 Uses of polypeptides NPSR1, SCTR, GRPR KDM4E 4438/4885GPR3 130/4885PTGER4 3969/4885
US-20240043745-A1 USE OF EUGENOL DERIVATIVES AS STABILIZERS, ORGANIC MATERIAL AND EUGENOL DERIVATIVES GSR, GAPDH, GPX4 KDM4E 760/4885GPR3 3345/4885PTGER4 1499/4885
US-20030207863-A1 Preventives and remedies for central nervous system diseases UTS2R, PRSS12, CTSA KDM4E 4866/4885GPR3 501/4885PTGER4 2883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.